Day: September 12, 2024

FOSTER CITY, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the closing of its previously announced underwritten public offering of 14,064,048 shares of its common stock, including 2,145,000 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a public offering price of $10.50 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,380,952 shares of its common stock, at a public offering price of $10.4999 per pre-funded warrant, in each case before underwriting discounts and commissions. The...

CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the pricing of its initial public offering of 10,200,000 shares of its common stock at a price to the public of $16.00 per share. The gross proceeds to MBX Biosciences from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $163.2 million. All of the shares are being offered by MBX Biosciences. In addition, MBX Biosciences has granted the underwriters a 30-day option to buy an additional 1,530,000 shares of its common stock at the initial public offering price, less underwriting...

Not for dissemination in the United States of America VANCOUVER, British Columbia, Sept. 12, 2024 (GLOBE NEWSWIRE) — Premier Diversified Holdings Inc. (“PDH” or the “Company”) (TSXV:PDH) announces that, further to the Notice of Meeting dated August 9, 2024 regarding the Company’s annual general and special meeting of shareholders (the “Meeting“) to be held on September 13, 2024 at 3:00PM (Vancouver time), shareholders of the Company are invited to virtually attend the Meeting by visiting the URL: meetnow.global/M2LDH9C. The Company’s Notice of Meeting, Information Circular and Form of Proxy in respect of the Meeting are available on SEDAR+ at www.sedarplus.com and were mailed to the Company’s shareholders. On behalf of the Board of Directors “Sanjeev Parsad” Sanjeev...

LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) — MURANO GLOBAL INVESTMENTS PLC (“Murano” or the “Company”) (NYSE: MRNO), announced today the closing of an offering of U.S.$300,000,000 aggregate principal amount of 11.000% Senior Secured Notes due 2031 (the “Notes”) by (i) a trust created under the laws of Mexico (such trust, the “Issuer Trust”). The Notes are guaranteed by Murano PV, S.A. de C.V., a Murano sub-holding entity incorporated in Mexico (the “Murano Parent Guarantor”), Operadora Hotelera G.I., S.A. de C.V. (the “Operator Guarantor”), and two other Mexican law-governed trusts (the “Murano 2000 Trust” and the “Murano 3224 Trust”). Murano acted as sponsor of the Notes issuance pursuant to a Sponsor Support and Indemnification Agreement. The main source of payment of the Notes will be the amounts corresponding to the collection...

NEW YORK, Sept. 12, 2024 (GLOBE NEWSWIRE) —  Logan Ridge Finance Corporation (Nasdaq: LRFC) (the “Company”) today announced that as of September 10, 2024, it has exited its largest equity investment, Nth Degree Investment Group, LLC (“Nth Degree”), at or above its previously reported fair value as of June 30, 2024. Ted Goldthorpe, Chief Executive Officer and President of Logan Ridge, said, “The rotation out of the legacy equity portfolio has been a key component of the turnaround strategy for Logan Ridge since Mount Logan Management took over as the Company’s investment advisor in July of 2021. We see the sale of Nth Degree, our largest equity position, as a transformative event and an important milestone for the Company. The cash proceeds from this transaction will be redeployed into interest earning assets originated by the BC...

JERICHO, N.Y., Sept. 12, 2024 (GLOBE NEWSWIRE) — Kimco Realty Corporation (NYSE: KIM) (the “Company”) today announced that its subsidiary, Kimco Realty OP, LLC (“Kimco OP” and, together with the Company, “Kimco”), has priced a public offering of $500 million aggregate principal amount of 4.850% notes due 2035 (the “notes”) with an effective yield of 4.873%, maturing March 1, 2035. The notes will be fully and unconditionally guaranteed by the Company. The offering is expected to settle on September 16, 2024, subject to the satisfaction of customary closing conditions. Kimco intends to use the net proceeds from the offering for general corporate purposes, including, but not limited to, funding for suitable investments and redevelopment opportunities and the repayment of outstanding indebtedness at or in advance of maturity. BofA...

LONDON, Sept. 12, 2024 (GLOBE NEWSWIRE) — Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, 2024, at 10:55am ET / 03:55pm BST. A live audio webcast can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available on the Company’s website for two weeks following the live event.  About Mereo BioPharmaMereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has two rare disease product candidates,...

CALGARY, Alberta, Sept. 12, 2024 (GLOBE NEWSWIRE) —  XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that it has refiled its management’s discussion and analysis (“MD&A”) for the financial year ended December 31, 2023 and for the interim period ended June 30, 2024 as a result of a continuous disclosure review by the Alberta Securities Commission. The originally filed MD&A for the financial year ended December 31, 2023 included an abbreviated definition of Disclosure Controls and Procedures under the section Internal Controls Over Financial Reporting. The amended MD&A for the financial year ended December 31, 2023 includes...